Fighting ALS, dementia and more by trapping toxic brain proteins

Blue purple pink 3d rendering of brain
If trapping toxic TDP-43 proves effective in ALS, it could be applied to many other neurological disorders. (monsitj / iStock / Getty Images Plus)

A pathological form of the protein TDP-43 that’s prone to clumping up in the brain has been implicated in 97% of amyotrophic lateral sclerosis (ALS) diagnoses. It’s also to blame for some cases of Alzheimer’s, chronic traumatic encephalopathy and frontotemporal dementia. But what if TDP-43 could be harnessed in a way that prevents it from forming those toxic clumps?

That’s the strategy researchers at the University of Pittsburgh are pursuing. They’ve developed an “oligonucleotide,” a short strand of RNA, that can prevent TDP-43 from building up in neurons. They described the method in the journal Neuron.

The research team started by reproducing toxic TDP-43 in a dish, using light pulses to coax the protein to form harmful balls. They noticed that the technique only worked when the protein lacked “RNA binding partners,” which normally fuse together to prevent clumping. So they created oligonucleotides that mimic RNA binding partners.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We call them 'bait-oligonucleotides,’” said senior author Christopher Donnelly, Ph.D., assistant professor of neurobiology and scientific director of the LiveLikeLou Center for ALS Research at the University of Pittsburgh Brain Institute, in a statement. “If you're fishing, you're trying to use bait to trap the fish. In our case, we're leaving the bait there for the extra protein to keep it from clumping together.”

RELATED: ALS researchers at Harvard uncover new biomarker and drug target

Most efforts to address errant TDP-43 to date have targeted the gene that produces the protein. In January, for example, Harvard researchers announced they discovered a connection between the TDP-43 gene and another gene, Stathmin2 (STMN2). They found that STMN2 deteriorates in lockstep with TDP-43, which hampers the repair of damaged neurons.

Last year, researchers at the University of Pennsylvania demonstrated that PARP inhibitors, which are currently on the market to treat some cancers with BRCA mutations, can prevent the abnormal clumping of TDP-43 by interfering with its ability to bind with a molecule called poly(ADP-ribose).

The University of Pittsburgh researchers believe that targeting the aggregation of TDP-43 rather than the gene directly could result in a therapy that’s broadly applicable to many brain diseases.

"The problem is the vast majority of patients with neurodegenerative disorders do not have specific mutations," Donnelly said. "Instead of targeting the gene that causes disease in a subset of patients, we're targeting the proteins that clump in nearly all of them.”

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.